Assembly Biosciences (NASDAQ:ASMB) Shares Cross Above 200-Day Moving Average – Here’s What Happened

Assembly Biosciences, Inc. (NASDAQ:ASMB)’s stock price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $27.02 and traded as high as $33.71. Assembly Biosciences shares last traded at $31.74, with a volume of 110,684 shares changing hands.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on ASMB. Weiss Ratings restated a “sell (d-)” rating on shares of Assembly Biosciences in a report on Wednesday, October 8th. JMP Securities started coverage on shares of Assembly Biosciences in a report on Wednesday, September 24th. They issued a “market outperform” rating and a $38.00 price objective for the company. Citigroup began coverage on shares of Assembly Biosciences in a research note on Wednesday, September 24th. They set an “outperform” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Assembly Biosciences in a research note on Monday, December 22nd. Finally, Mizuho set a $40.00 price objective on Assembly Biosciences and gave the company an “outperform” rating in a research report on Thursday, November 20th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $41.00.

Assembly Biosciences Stock Up 0.6%

The stock’s fifty day simple moving average is $34.36 and its two-hundred day simple moving average is $27.09. The firm has a market cap of $502.03 million, a PE ratio of -6.63 and a beta of 1.14.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings results on Monday, November 10th. The biopharmaceutical company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.22). Assembly Biosciences had a negative return on equity of 59.01% and a negative net margin of 103.65%.The company had revenue of $10.79 million during the quarter, compared to analysts’ expectations of $7.46 million. On average, equities research analysts anticipate that Assembly Biosciences, Inc. will post -6.87 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE boosted its stake in shares of Assembly Biosciences by 6,382.7% during the 3rd quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 3,319 shares during the last quarter. Qube Research & Technologies Ltd purchased a new stake in shares of Assembly Biosciences during the third quarter worth about $282,000. Palumbo Wealth Management LLC raised its stake in Assembly Biosciences by 3.8% during the 2nd quarter. Palumbo Wealth Management LLC now owns 18,667 shares of the biopharmaceutical company’s stock valued at $338,000 after purchasing an additional 681 shares during the period. ADAR1 Capital Management LLC bought a new position in Assembly Biosciences in the 3rd quarter worth approximately $485,000. Finally, Millennium Management LLC bought a new stake in shares of Assembly Biosciences during the third quarter valued at approximately $553,000. Institutional investors own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.